葡萄牙语肌萎缩侧索硬化症患者的甲状腺功能障碍。

Thyroid dysfunction in Portuguese amyotrophic lateral sclerosis patients.

机构信息

Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa-Norte, 1649-035, Lisbon, Portugal.

Faculdade de Medicina- Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal.

出版信息

Neurol Sci. 2022 Sep;43(9):5625-5627. doi: 10.1007/s10072-022-06135-3. Epub 2022 May 27.

DOI:10.1007/s10072-022-06135-3

PMID:35622209

Abstract

INTRODUCTION

Thyroid hormones influence neuromuscular function, and it has been thought that this might contribute to degeneration of motor neurons.

METHODS

We used case-control methods to investigate the prevalence of thyroid dysfunction (hyperthyroidism and hypothyroidism) in ALS patients followed in our centre, between 2015 and 2020. Data from patients with neuromuscular disorders not derived from thyroid dysfunction, followed within the same time frame, were used as controls. Thyroid dysfunction was defined by previous thyroid replacement medication managed by an endocrinologist. We used odds ratios (OR) with a 95% confidence interval (CI) to compare 579 ALS patients and 415 age-gender-matched disease controls. Additionally, we provide a summarized review of the literature.

RESULTS

Hypothyroidism (prevalence of 5.0 versus 8.6%; OR = 0.56, 95% CI 0.34-0.92, p = 0.023), hyperthyroidism (prevalence of 0.3 versus 1.2%; OR = 0.28, 95% CI 0.06-1.47, p = 0.134) and overall thyroid dysfunction (prevalence of 5.4 versus 9.9%; OR = 0.52, 95% CI 0.32-0.84, p = 0.015) were less prevalent in ALS patients than in controls, but similar to the national epidemiological data for thyroid disease. Our data are in line with the findings of most previous studies.

CONCLUSIONS

We conclude that thyroid dysfunction is not associated with ALS.

摘要

简介

甲状腺激素会影响神经肌肉功能，因此人们认为这可能会导致运动神经元退化。

方法

我们使用病例对照方法，调查了我们中心在 2015 年至 2020 年间随访的 ALS 患者中甲状腺功能障碍（甲状腺功能亢进和甲状腺功能减退）的患病率。同时，我们还调查了同一时期患有非甲状腺功能障碍引起的神经肌肉疾病的患者作为对照。甲状腺功能障碍的定义是由内分泌医生管理的先前甲状腺替代药物治疗。我们使用比值比（OR）及其 95%置信区间（CI）来比较 579 名 ALS 患者和 415 名年龄、性别匹配的疾病对照。此外，我们还提供了文献综述。

结果

与对照组相比，甲状腺功能减退症（患病率为 5.0% vs. 8.6%；OR = 0.56，95%CI 0.34-0.92，p = 0.023）、甲状腺功能亢进症（患病率为 0.3% vs. 1.2%；OR = 0.28，95%CI 0.06-1.47，p = 0.134）和总体甲状腺功能障碍（患病率为 5.4% vs. 9.9%；OR = 0.52，95%CI 0.32-0.84，p = 0.015）的患病率均较低，但与全国甲状腺疾病的流行病学数据相似。我们的数据与大多数先前研究的结果一致。